心肌细胞的重塑:研究症状性缺血性心力衰竭之前的形态细胞变化
Milda Kuprytė1, Vaiva Lesauskaitė2, Vytenis Keturakis1
1Laboratory of Cardiac Pathology, Institute of Cardiology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
International journal of molecular sciences
|October 14, 2023
概括
心肌细胞 (心肌细胞) 和它们的内部支架的早期结构变化发生在症状性缺血性心力衰竭 (HF) 之前. 这些重塑事件涉及大小,形状和表达的显著变化,提供了对HF病变的见解.
科学领域:
- 心血管生物学 心血管生物学
- 细胞形态 细胞形态
- 病理生理学 病理生理学
背景情况:
- 已知心力衰竭 (HF) 发病机制,但早期心肌细胞变化之前的症状尚不清楚.
- 了解早期的结构性心肌细胞重塑对于确定缺血性高血压的治疗点至关重要.
研究的目的:
- 为了表征心肌细胞的形态变化.
- 为了研究在临床前缺血性心力衰竭期间的中间线索重组.
- 分析与HF阶段相关的desmin表达.
主要方法:
- 对84个人类心脏组织样本进行了基组形态测量和免疫组织化学分析.
- 评估心肌细胞的大小,形状和表达方式.
- 将样品分类为ACC/AHA HF A,B和C/D阶段.
主要成果:
- 心肌细胞的大小和体积从A阶段HF显著增加,主要是直径,并在C/D阶段HF显著增加,主要是长度.
- 德斯敏表达在A阶段HF升高,在C/D阶段HF达到峰值.
- 显著的心肌细胞形态变化和细胞骨重组在症状性缺血性HF之前.
结论:
- 在症状性缺血性心力衰竭之前,心肌细胞及其细胞骨架网络的早期适应性结构变化是显而易见的.
- 这些发现强调了早期细胞重塑在HF发育中的重要性.
- 这些临床前变化的表征为未来的诊断和治疗策略提供了基础.
相关概念视频
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Myocarditis I: Introduction
9
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
9
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11


